AI English summary of an SEC filing — figures as filed
Dexcom DXCMThe company said worldwide revenue for Q2 2024 grew 15% on a reported basis to $1.004 billion, up from $871.3 million in Q2 2023. U.S. revenue grew 19%, and international revenue grew 7% on a reported basis.
Key points
AI summaryThe company said worldwide revenue for Q2 2024 grew 15% on a reported basis to $1.004 billion, up from $871.3 million in Q2 2023. U.S. revenue grew 19%, and international revenue grew 7% on a reported basis.
DexCom said GAAP operating income for Q2 was $158.0 million, or 15.7% of revenue, and GAAP net income was $143.5 million, or $0.35 per diluted share. For Q2 2023, operating income was $128.1 million and net income was $115.9 million.
The company updated its full-year 2024 revenue guidance to approximately $4.00 to 4.05 billion, or 11 to 13% organic growth, and set its third-quarter revenue outlook at approximately $975 million to $1.00 billion, or 1 to 3% organic growth for Q3.
The company said its Board of Directors authorized a share repurchase program of up to $750.0 million of common stock, with a repurchase period ending no later than June 30, 2025. The program does not obligate the company to repurchase any specific dollar amount or number of shares.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
QQ2 revenue of $1.004 billion, up 15% on a reported basis
The company said worldwide revenue for Q2 2024 grew 15% on a reported basis to $1.004 billion, up from $871.3 million in Q2 2023. U.S. revenue grew 19%, and international revenue grew 7% on a reported basis.
Source · Based on the filing body and exhibits
Q2 GAAP operating income of $158.0 million, net income of $143.5 million
DexCom said GAAP operating income for Q2 was $158.0 million, or 15.7% of revenue, and GAAP net income was $143.5 million, or $0.35 per diluted share. For Q2 2023, operating income was $128.1 million and net income was $115.9 million.
Source · Based on the filing body and exhibits
Full-year revenue outlook of $4.00 to 4.05 billion, Q3 outlook provided
The company updated its full-year 2024 revenue guidance to approximately $4.00 to 4.05 billion, or 11 to 13% organic growth, and set its third-quarter revenue outlook at approximately $975 million to $1.00 billion, or 1 to 3% organic growth for Q3.
Source · Based on the filing body and exhibits
Board approves up to $750.0 million share buyback program
The company said its Board of Directors authorized a share repurchase program of up to $750.0 million of common stock, with a repurchase period ending no later than June 30, 2025. The program does not obligate the company to repurchase any specific dollar amount or number of shares.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…